Back to Search
Start Over
Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence.
- Source :
-
The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2022 Jun; Vol. 10 (6), pp. 384-385. - Publication Year :
- 2022
-
Abstract
- Competing Interests: OC reports personal fees for giving lectures at congress and travel to congress from Novartis, Recordati, HRA Pharma, and Pfizer; and fees for being co-investigator in clinical research studies funded by Novartis, Recordati, and HRA Pharma. All other authors declare no competing interests.
Details
- Language :
- English
- ISSN :
- 2213-8595
- Volume :
- 10
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- The lancet. Diabetes & endocrinology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 35597254
- Full Text :
- https://doi.org/10.1016/S2213-8587(22)00134-6